| Name | Title | Contact Details |
|---|
Mr. Gallagher is Senior Vice President & Chief Financial Officer at RRD International, LLC. Mr. Gallagher provides strategic, operational, and financial leadership to RRD. His primary responsibilities are planning, implementing, managing, and controlling all financial-related activities including the development of financial and operational strategies. Mr. Gallagher has over 20 years of finance experience in the biopharma industry with both multi-national corporations and commercial-stage public biotechnology companies. He has an extensive background in all areas of corporate controllership, including financial planning & analysis, cost control, management accounting, corporate administration, and systems implementation. He has supported all aspects of product development and commercialization, including the negotiation and execution of licensing and collaboration agreements with major pharma partners. Mr. Gallagher served previously as Vice President of Finance for Optimer Pharmaceuticals and, prior to that, as Senior Director of Finance and Corporate Controller for Adolor Corporation. He had a central role in the sale of both companies. Mr. Gallagher spent the first 10 years of his career with Therakos, Inc. (a Johnson & Johnson company) and Merck & Co., Inc. He received his BS in Finance from The Pennsylvania State University and is an active Certified Management Accountant (CMA).
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
Prison Health Services is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products.
Sleep Disorder Center of Louisiana is a Lake Charles, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.